Together with our findings, those researches suggested that the therapeutic effect of YSNJF in MDS treatment might be achieved by promoting tumor cell death and maintain homeostasis of the hematopoietic system through regulating MAPK and PI3K-AKT signaling pathways. The gene discussed is AKT1; the disease is myelodysplastic syndrome.